Table 2.

Multivariate analysis of progression-free survival and overall survival

Progression-free survivalaOverall survivalb
HR (95% CI)PHR (95% CI)P
Outcome group
 Predicted worse vs. predicted better1.38 (0.73–2.59)0.2033.16 (1.56–6.40)0.001
Stage
 4 vs. 3C1.18 (0.57–2.44)0.3091.14 (0.52–2.49)0.742
Debulking
 vs. Complete macroscopic0.63 (0.33–1.21)0.1682.57 (1.25–5.28)0.01
BRCA Mutated
 WT vs. Mutated1.06 (0.49–2.32)0.8771.28 (0.50–3.28)0.611
 CA125 Reductionc0.98 (0.96–0.99)0.0050.99 (0.98–1.00)0.153
 Age0.99 (0.98–1.02)0.9701.04 (1.01–1.06)0.007
  • NOTE: The effect of genetics on overall and progression-free survival on our patient population was assessed controlling for clinical characteristics known to affect survival in patients with HGSC.

  • aPFS was defined as time of diagnosis to time of evidence of recurrence by imaging, death or last follow-up.

  • bOS was defined as time of diagnosis to time of death or last follow-up.

  • cPercentage of reduction in CA125 value before and after NACT treatment before surgery.